Promising ARDS drug trial pulled before it even started

NCT ID NCT03017547

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test whether IC14, a drug that blocks a key inflammatory signal, could help people with acute respiratory distress syndrome (ARDS). The plan was to give IC14 or a placebo to about 100 ICU patients and see if it reduced time on a ventilator. However, the trial was withdrawn before enrolling anyone, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IC14 (a monoclonal antibody that blocks CD14 signaling)

What this could lead to

If it had worked, this could have pointed toward a new treatment for ARDS by reducing inflammation in the lungs.

What could go wrong

The trial was withdrawn before any patients were enrolled, so no results are available. Early-phase studies often fail to show benefit in larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.